Skip to main content
Premium Trial:

Request an Annual Quote

Beckman Coulter To Acquire Chemiluminescent Chemistry Provider Lumigen for $185M

NEW YORK (GenomeWeb News) – Beckman Coulter said yesterday that it has signed an agreement to acquire Lumigen for $185 million.
 
Lumigen, based in Southfield, Mich., provides detection chemistries for clinical diagnostics and life science research. 
 
Beckman Coulter currently uses Lumigen’s proprietary chemiluminescent chemistry for its Access family of immunoassay systems.
 
Sales of Lumigen's chemiluminescent substrate to Beckman Coulter accounted for about 40 percent, or $13.2 million, of Lumigen’s reported 2005 revenues of $33 million.
 
Beckman said that the acquisition will ensure it has continued access to Lumigen's current and future immunochemical and other high-sensitivity testing products.
 
The all-cash deal is expected to close by Nov. 1.